Noxopharm (ASX:NOX) Moves Ahead with Key Biotechnology Initiative

Aditi Sarkar

20 May 2026 05:51 PM AEST

Noxopharm (ASX:NOX) Moves Ahead with Key Biotechnology Initiative

Image Source: shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Noxopharm announced that data involving its Sofra technology Assets will be presented at a major international conference.
The presentation will be delivered by CSL at the Options for the Control of Influenza XIII Conference in Washington DC.
The project relates to improving delivery of self-amplifying mRNA vaccines using Sofra oligonucleotides.
Sofra technology targets inflammation, autoimmune diseases, RNA therapeutics and Vaccine applications.
Noxopharm highlighted the broader versatility and industry interest surrounding the Sofra platform.

Noxopharm Ltd (ASX:NOX) has announced that data connected to its Sofra technology platform will be presented at a major international scientific conference later this year, highlighting the company’s ongoing work in RNA therapeutics and vaccine-related applications.

According to the company, the presentation will be delivered by global biopharmaceutical company CSL at the upcoming Options for the Control of Influenza XIII Conference scheduled to take place in Washington DC in late August 2026.

Noxopharm shares traded at AUD 0.064 on 19 May 2026 as investors continued monitoring developments linked to the company’s biotechnology pipeline and platform-based therapeutic programs.

The data presentation relates to research involving Noxopharm’s proprietary oligonucleotide assets from the Sofra platform and their potential role in improving the delivery of self-amplifying mRNA vaccines.

The latest update reflects growing external engagement surrounding Sofra and its potential applications across inflammation-related diseases, RNA therapeutics and immunology-focused treatment areas.

Sofra Platform Positioned Across Multiple Therapeutic Areas

Noxopharm described Sofra as a novel drug platform developed from a breakthrough discovery involving the immune system.

The technology is designed to regulate innate immune signalling with the goal of influencing inflammatory responses at their source. According to the company, Sofra has potential applications across inflammatory diseases, autoimmune conditions, RNA therapeutics, vaccines and oncology-related treatment approaches.

The company explained that Sofra uses short nucleic acid sequences known as oligonucleotides. These molecules are designed to interact with specific immune sensors to either reduce or stimulate inflammatory responses depending on the therapeutic objective.

Noxopharm stated that the platform could potentially be applied to immune-related conditions including rheumatoid arthritis, lupus and diabetes, while also offering possible applications in cancer therapies and reducing off-target effects associated with RNA-based medicines.

The company’s latest announcement particularly focused on Sofra’s relevance to vaccine delivery technologies involving self-amplifying mRNA platforms.

CSL Presentation Highlights Industry Engagement

The upcoming conference presentation by CSL represents another stage in the ongoing collaboration involving Noxopharm’s Sofra assets.

The research being presented examines how Sofra-derived oligonucleotides could potentially improve delivery mechanisms for self-amplifying mRNA vaccines.

Self-amplifying mRNA vaccines are designed to replicate genetic material inside cells after administration, potentially allowing lower dosing requirements while maintaining immune responses. Delivery systems remain an important aspect of advancing RNA-based therapeutics and vaccine technologies.

The presentation is scheduled for the Options for the Control of Influenza XIII Conference, which Noxopharm described as one of the largest global scientific meetings dedicated to influenza prevention, treatment and control.

The conference brings together specialists across virology, vaccine development, clinical care and public health sectors to discuss emerging research and scientific developments related to influenza and vaccine technologies.

Noxopharm’s involvement through the CSL presentation may therefore provide additional international visibility for the Sofra platform within the broader scientific and biotechnology community.

Management Highlights Growing Interest in Sofra

Noxopharm Chief Executive Officer Dr Olivier Laczka commented that the Sofra platform continues attracting interest due to both its scientific foundation and its versatility across multiple therapeutic areas.

Management indicated that the company has continued progressing the platform toward broader applications involving inflammation, RNA therapeutics and vaccine enhancement.

Dr Laczka stated that inflammation plays a role across many disease areas and highlighted the company’s efforts in advancing Sofra toward practical development opportunities.

The company also noted that the platform’s scientific foundation is based on what it described as a breakthrough understanding of the immune system.

As biotechnology companies continue exploring applications for RNA-based medicines and immunomodulatory therapies, platforms capable of supporting delivery, safety or immune regulation remain areas of active industry research.

Growing Markets for Autoimmune and Immuno-Oncology Treatments

Noxopharm’s announcement also referenced the broader commercial markets connected to Sofra’s potential applications.

According to figures cited by the company, the global autoimmune disease therapeutics market was valued at approximately US$163.2 billion in 2024 and is projected to reach US$219.6 billion by 2035.

The company additionally noted that the global immuno-oncology market was valued at around US$43 billion in 2023 and could potentially expand to US$284 billion by 2033.

These markets continue attracting Investment and research activity as pharmaceutical and biotechnology groups pursue new therapies targeting immune pathways, inflammatory diseases and cancer-related treatments.

By positioning Sofra across multiple therapeutic categories, Noxopharm appears to be pursuing opportunities spanning both inflammatory diseases and advanced RNA medicine applications.

Noxopharm Continues Expanding Its Biotechnology Pipeline

Noxopharm is a clinical-stage Australian biotechnology company focused on developing therapies linked to cancer treatment, inflammation and RNA medicine technologies.

The company currently operates through two primary technology platforms — Sofra and Chroma.

While Sofra focuses on inflammation, autoimmunity, RNA therapeutics and oncology-related applications, the Chroma platform is centred on oncology development activities.

Noxopharm stated that it continues utilising internal research capabilities and strategic scientific partnerships to expand its proprietary Drug Development pipeline.

The latest update involving CSL and the upcoming international conference presentation reflects the company’s ongoing efforts to increase industry engagement and scientific visibility surrounding its technologies.

Focus on RNA Therapeutics and Vaccine Technologies

RNA therapeutics and mRNA-based vaccines have remained important areas of biotechnology research in recent years, particularly as companies seek to improve delivery systems, efficacy profiles and safety characteristics.

Noxopharm’s update highlights Sofra’s potential relevance within this evolving segment, particularly through its possible role in supporting self-amplifying mRNA vaccine delivery.

The company also indicated that Sofra may help address off-target effects associated with RNA therapeutics, which remains an important consideration across RNA medicine development programs.

As industry research into mRNA applications continues expanding beyond infectious diseases into oncology and other therapeutic areas, technologies supporting immune regulation and targeted delivery could continue attracting attention from biotechnology and pharmaceutical companies.

What This Means for Investors?

Noxopharm’s latest update highlights growing scientific visibility for its Sofra technology platform through an upcoming international conference presentation involving CSL.

The presentation may provide additional exposure for Sofra’s potential applications in RNA therapeutics and vaccine delivery, particularly within the emerging self-amplifying mRNA field.

Investors are likely to continue monitoring future research developments, Partnership activities and clinical progress connected to Noxopharm’s broader biotechnology pipeline as the company advances both its Sofra and Chroma platforms.

FAQs

Q: What did Noxopharm announce on 20 May 2026?

A: Noxopharm announced that data involving its Sofra technology assets will be presented by CSL at the Options for the Control of Influenza XIII Conference in Washington DC.

Q: What is the Sofra platform?

A: Sofra is Noxopharm’s proprietary technology platform designed to regulate innate immune signalling for applications involving inflammation, autoimmune diseases, RNA therapeutics, vaccines and oncology.

Q: What is the focus of the upcoming conference presentation?

A: The presentation relates to how Sofra oligonucleotides could potentially improve delivery of self-amplifying mRNA vaccines.

Q: What is the Options for the Control of Influenza Conference?

A: It is a major international scientific conference focused on influenza prevention, treatment, vaccine research and public health.

Q: What other therapeutic areas could Sofra target?

A: According to Noxopharm, Sofra may have applications in conditions such as rheumatoid arthritis, lupus, diabetes, cancer therapies and RNA medicine enhancement.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.